On April 3, 2024 TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, reported the successful completion of acceptance testing and regulatory registration inspection of its accelerator- based neutron beam system (NBS), marking a significant milestone in BNCT global market adoption (Press release, TAE Life Sciences, APR 3, 2024, View Source [SID1234641747]). Developed and manufactured in the United States, TAE Life Sciences’ NBS has met all specifications outlined by Neuboron Medical and the local regulatory body, enabling human BNCT clinical trials to begin this month in China.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The completion of acceptance testing underscores TAE Life Sciences’ commitment to international safety and efficacy standards, making it the first US company to have its system achieve such recognition. This major technological progress demonstrates how TAE Life Sciences has solidified its leading position in the growing field of BNCT. As the company progresses in establishing Alphabeam BNCT sites worldwide, collaborating with Neuboron to provide them with a Neutron Beam System has paved a distinctive pathway into the Chinese market.
"We worked closely with Neuboron to ensure our accelerator-based NBS precisely delivered the results required for BNCT and are thrilled to have successfully completed acceptance testing and regulatory inspection," stated Rob Hill, CEO at TAE Life Sciences. "This milestone not only demonstrates our dedication to delivering cutting-edge cancer treatment solutions, but also signifies our ability to meet rigorous international standards."
Additionally, the Beijing Institute of Medical Device Testing has completed registration testing of the full Neuboron Medical’s NeuPex AB-BNCT system, which includes TAE Life Science’s NBS. This milestone marks a significant regulatory approval step, enabling Neuboron to move forward with clinical trials in China. Neuboron will commence clinical trials at Xiamen Humanity Hospital.
The latest market analysis report by Intel Market Research forecasts robust growth in the BNCT market, with global revenues projected to reach $2.2 billion by 2030. TAE Life Sciences, alongside industry leaders such as Neuboron, Sumitomo, and others, is poised to play a pivotal role in driving this exponential growth.
As the BNCT market continues to expand, TAE Life Sciences remains at the forefront of innovation, delivering transformative solutions to cancer patients worldwide.
For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit taelifesciences.com.
For more information about Neuboron and its technologies, please visit neuboron.com/.